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Two recent reports in Nature provide evidence for increasingly complex ‘‘disruptive’’ molecular alterations
that occur during prostate cancer progression. They shed light on the intricacy of genetic changes that
modulate PTEN’s control over the phosphoinositide 3-kinase pathway and prostate cancer progression,
and identify new potential biomarkers and therapeutic targets.The number of genomic changes ob-
served in cancer is rapidly expanding,
due to the emergence of enabling technol-
ogies. In prostate cancer, approximately
half of all tumors harbor rearrangements,
which frequently render a gene from
the ETS family of transcription factors
under the control of androgen-regulated
promoter elements (Tomlins et al., 2005)
(Figure 1). Another well-established set
of molecular alterations in this disease
are mutations in the tumor suppressor
gene PTEN, which lead to activation of
phosphoinositide 3-kinase (PI3K)/AKT
pathways (Li et al., 1997) and cooperate
with ETS fusions in prostate carcinogen-
esis (Carver et al., 2009; King et al.,
2009). While many prostate cancers can
be characterized by ETS and/or PTEN
status, additional ‘‘disruptive’’ events
—genomic events with promalignant
consequences—are being identified in
smaller subsets of disease that exemplify
the enormous genomic complexity of
prostate cancer.
With the goal of identifying novel
somatic events in prostate cancer, Berger
et al.(2011) recently completed whole
genome sequencing of seven primary
prostate cancers (three harboring ETS
rearrangements) and their matched
normal controls. This led to the identifica-
tion (and in some cases reconfirmation) of
mutations in several genes, including
SPTA1, SPOP, ZNF407, CHD1, CHD5,
HDAC9, DICER and PTEN. As is often
the case with genomic changes that drive
cancer progression, it is common to find
functionally recurrent mutations that
disrupt multiple genes in a pathway.Specifically, rearrangements disrupting
both PTEN and its interacting protein
MAGI2 were identified. Knockdown
experiments may further confirm that the
loss of MAGI2 expression drives AKT
phosphorylation, suggesting that suscep-
tibility pathways can be mutated at
different points and expanding the
number of mutations known to disrupt
PTEN signaling in prostate cancer.
Since these data reveal that multiple
disruptive genomic events can alter PI3K
signaling, it is not surprising that geneti-
cally engineered mouse models with
PTEN and ETS lesions do not fully recapit-
ulate the disease phenotypes of human
prostate cancer. In fact, mice with either
prostate-specific overexpression of
TMPRSS2-ERG (the predominant ETS
fusion) or PTEN loss of heterozygosity
only develop precursor-like lesions of
prostate cancer, called prostate intraepi-
thelial neoplasia (PIN), which in the case
of complete PTEN inactivation can prog-
ress to high-grade adenocarcinoma after
long latency (Chen et al., 2005). When
ERG is overexpressed in a PTEN hetero-
zygous background, mice develop inva-
sive prostate cancer more rapidly than
control mice (Carver et al., 2009; King
et al., 2009), but without a reported
propensity for distant metastasis. These
models suggested that either a funda-
mental difference between mice and
men exists—especially considering that
wild-type mice do not develop prostate
cancer—or that we do not yet have
a complete understanding of all of the
disruptive events that occur prior to meta-
static progression.Cancer Cell 1Following the latter postulation that
additional unknown barriers are prevent-
ing metastatic progression, Ding et al.
(2011) recently compared the gene
expression profiles of PTEN deletion-
induced PIN to wild-type prostate epithe-
lium. This led to the identification of
a difference in expression of genes in the
TGFb signaling pathway. Subsequent
prioritization of targets in this pathway
led to the identification of SMAD4 as
a key regulator of TGFb signaling that is
downregulated in human prostate cancer
metastasis as compared with localized
prostate cancer. Importantly, prostate-
specific deletion of both SMAD4 and
PTEN led to faster occurring prostate
cancer with a high propensity for metas-
tasis, while SMAD4 deletion alone had
no effect. This suggested that before
PTEN-impaired prostate tumors become
metastatic, they must first develop mech-
anisms to disrupt the tumor suppressive
effects of SMAD4-mediated canonical
TGFb signaling. It will be interesting to
see if genomic sequencing of metastatic
prostate cancer reveals evidence of
TGFb pathway disruption.
Although Berger et al. did not identify
events disrupting TGFb signaling, their
study provides insight into the mecha-
nism of how gene fusions are formed.
For example, many of the rearrangements
occurred in a balanced manner such that
reciprocal genomic rearrangements are
generated, creating a series of many
different gene fusions in which no DNA
copy number changes were identified
(Berger et al., 2011). This study also found
that a single gene could be disrupted by9, March 15, 2011 ª2011 Elsevier Inc. 301
Figure 1. Disruptive Events Found in Primary Prostate Cancer
Rearrangements and base substitution mutations disrupting several pathways have been identified
in localized prostate cancer, including rearrangements driving ETS transcription factor overexpression,
rearrangements causing constitutive RAF kinase activation, epigenetic changes to the SMAD4 locus
blocking TGFb signaling (Ding et al., 2011), and rearrangements/mutations disrupting PI3K signaling
(such as PTEN and MAGI2) (Berger et al., 2011). Likewise, mutations in an E3-ubiquitin ligase gene
(SPOP) have been reported to occur in a subset of human prostate cancer (Berger et al., 2011). While
rearrangements of ETS and RAF genes appear to be mutually exclusive, it is still unknown whether the
other disruptive mutations will collaborate.
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in each tumor. For example, they identi-
fied rearrangements that occur in approx-
imately 6% of prostate cancers in a cell
adhesion gene called CADM2, and each
rearrangement occurred by a different
combination of genomic deletions, dupli-
cations, and inversions. This suggests
that while the type of rearrangement
may be different, a conservedmechanism
must be responsible for creating a rear-
rangement ‘‘hotspot.’’
By overlapping the breakpoint loca-
tions with available genome-wide location
analyses for androgen receptor (AR),
ERG, and histone marks (Yu et al.,
2010), Berger et al. demonstrated that
the breakpoints correlated with open
chromatin marks as well as AR binding
in tumors with ETS rearrangements. This
is surprising, as the most common ETS
gene fusion product, ERG, functions to
disrupt AR signaling (Yu et al., 2010).It
will be interesting to see if other genomic
events correlated with ETS status, such
as chromosome 3p14 deletion, are also
correlated with enrichment of these
factors (Taylor et al., 2010). Nonetheless,
this observation supports recent mecha-
nistic data suggesting that activated AR302 Cancer Cell 19, March 15, 2011 ª2011 Efacilitates genomic rearrangements by
bringing linearly distant genomic loci
together in a process termed induced-
proximity (multiple studies reviewed in
Mani and Chinnaiyan, 2010). The fact
that androgen receptor was enriched at
genomic breakpoints also suggests that
these ‘‘hotspots’’ may be tissue type
specific.
In addition to addressing how rear-
rangement breakpoints are selected, the
data also gave insight into the repair
mechanism that fuses the DNA ends after
breaks occur. For example, nonhomolo-
gous end joining frequently utilizes
regions of microhomology to facilitate
the ligation of otherwise noncompatible
DNA ends. Interestingly, most of the
called rearrangements were precise joins
without overlapping or intervening
sequence at the junction. In contrast,
analysis of sequence data used to analyze
breakpoints in breast cancer demon-
strated that most fusion junctions had
2-3bp of microhomology (Stephens
et al., 2009). It is tempting to speculate
that the DNA ends may be rejoined in
the two cancers by different repair
processes whose activities are cell cycle
dependent.lsevier Inc.Given the enormous complexity of
disruptive events in a prostate cancer
genome, an important question is: how
can this information be used clinically?
Recognizing the apparent mechanistic
importance of PTEN and SMAD4
signaling to prostate cancer progression,
Ding et al. (2011) identified two key effec-
tors of the TGFb signaling pathway, the
invasion-associated gene product SPP1
and the cell cycle regulator CyclinD1, to
help develop a test to predict for aggres-
sive disease. Subsequent expression
analysis of these four genes—PTEN,
SMAD4, CCND1, and SPP1—was able
to predict lethal metastasis in prostate
cancer better than Gleason score
alone (Ding et al., 2011). In light of the
ever-expanding number of recurrent
mutations in prostate cancer and the
fact that other events disrupting PI3K
signaling were not analyzed, this observa-
tion is all the more remarkable.
In conclusion, the recent reports by
Berger, Ding, and colleagues highlight
the complex nature of disruptive events
in the life of prostate cancer. As advanced
sequencing approaches become more
widely implemented, it is certain that
additional genetic alterations along key
progression pathways will be identified.
Understanding the genesis and effect of
these events, relative to existing lesions
such as PTEN inactivation and ETS
fusions, will be critical to the efforts to
develop better biomarker-based predic-
tors of progression and to identify poten-
tial targets for prostate cancer therapy.
While the discovery of key genetic alter-
ations, such as PTEN inactivation, ETS
and RAF fusions, SPOP mutations,
MAGI2 rearrangements, and SMAD4
silencing have represented significant
strides toward a better understanding of
prostate cancer progression, it is clear
that we are seeing just the tip of the
iceberg of cancer-defining disruptive
lesions, but are also at the beginning of
an exciting period of discovery.REFERENCES
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